慢性荨麻疹患者的自体全血注射治疗及自体血清皮肤试验阳性:一项安慰剂对照试验

作     者：Staubach P. Onnen K. Vonend A. M. Maurer 罗素菊 徐波 

作者机构：Department of Dermatology and Allergy Charité Universit tsmedizin Berlin Schumannstrasse 20- 21 DE- 10117 Berlin GermanyDr. 

出 版 物：《世界核心医学期刊文摘（皮肤病学分册）》 (Digest of the World Core Medical JOurnals:Dermatology)

年 卷 期：2006年第2卷第4期

页      面：48-48页

学科分类：1002[医学-临床医学] 100206[医学-皮肤病与性病学] 10[医学] 

主　　题：荨麻疹患者 体全 皮肤试验 自体血清 安慰剂对照 组胺释放因子 抗组胺药 慢性荨麻疹 肌内注射 症状 

摘      要：Background: Patients with chronic urticaria (CU) frequently exhibit positive skin test reactions to autologous serum (ASST). Therapies aimed at inducing tolerance to circulating histaminereleasing factors in ASST+ CU patients, e.g. by treatment with autologous whole blood (AWB), have not yet been tested. Objective: To test whether ASST+ CU patients can benefit from repeated low- dose intramuscular injections of AWB. Methods: We characterized CU severity and duration, anti- Fc∈ RI and anti- IgE expression, use of antihistamines, and quality of life in 56 CU patients (ASST+ : 35, ASST- : 21) and assessed the therapeutic effects of 8 weekly AWB injections in a randomized, placebo- controlled, single- blind, parallel- group trial. Results: Numbers, size, intensity, andor duration of CU symptoms, quality of life, as well as expression of anti- Fc∈ RI or anti- IgE were similar in ASST+ and ASST- CU patients. However, CU in ASST+ patients was of longer duration and required markedly more antihistaminic medication. Interestingly, ASST+ patients, but not ASST- patients, showed significantly (1) reduced CU activity, (2) decreased use of antihistamines, and (3) improved quality of life after AWB treatment. Placebo treatment was ineffective in both groups, but differences of AWB and placebo treatment responses did not achieve statistical significance in either group, most likely due to the limited number of patients treated. Conclusion: Our findings suggest that ASST+ CU is clinically different from other CU subforms and that ASST+ CU patients can benefit from AWB therapy.